• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

区分 V617F 型原发性血小板增多症与真性红细胞增多症:红细胞值的局限性。

Distinguishing essential thrombocythemia V617F from polycythemia vera: limitations of erythrocyte values.

机构信息

Richard T. Silver Myeloproliferative Neoplasm Center, Division of Hematology/Medical Oncology, Weill Cornell Medicine, New York, NY, USA

出版信息

Haematologica. 2019 Nov;104(11):2200-2205. doi: 10.3324/haematol.2018.213108. Epub 2019 Apr 4.

DOI:10.3324/haematol.2018.213108
PMID:30948488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6821600/
Abstract

Distinguishing essential thrombocythemia V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV), but their sensitivity and specificity were not tested. Moreover, red cell values do not accurately predict red cell mass, which we use to discriminate essential thrombocythemia V617F from PV. Eighty-three PV and 39 essential thrombocythemia V617F patients were diagnosed based on V617F positivity, chromium-51 red cell mass, and marrow biopsy findings. Red cell values used to construct a receiver operating characteristic analysis determined optimal thresholds for distinguishing essential thrombocythemia V617F from PV. Red cell value frequencies were plotted determining if overlap existed. Chromium-51 red cell mass separated PV from essential thrombocythemia V617F, but red cell values overlapped in 25.0-54.7%. Our data indicate that a significant proportion of PV patients may be underdiagnosed by using only red cell values. A bone marrow biopsy was performed in 199 of 410 (48.5%) and a serum erythropoietin value was measured in 225 of 410 (54.9%) of potential PV patients at our institution. Without isotope studies, marrow biopsies and serum erythropoietin values should improve diagnostic accuracy and become mandatory, but clinical data suggest these tests have not been routinely performed. Therefore, the clinical hematologist must be aware of imperfect accuracy when using only red cell values for distinguishing essential thrombocythemia V617F from PV.

摘要

从共同的突变和表型特征来看,区分原发性血小板增多症 V617F 和真性红细胞增多症是很困难的。世界卫生组织建议使用血红蛋白和血细胞比容值来诊断真性红细胞增多症(PV),但并未对其敏感性和特异性进行测试。此外,红细胞值不能准确预测红细胞量,我们使用红细胞量来区分原发性血小板增多症 V617F 和 PV。根据 V617F 阳性、铬 51 红细胞量和骨髓活检结果,诊断了 83 例真性红细胞增多症和 39 例原发性血小板增多症 V617F 患者。用于构建受试者工作特征分析的红细胞值确定了区分原发性血小板增多症 V617F 和 PV 的最佳阈值。绘制红细胞值频率图以确定是否存在重叠。铬 51 红细胞量可将 PV 与原发性血小板增多症 V617F 区分开来,但红细胞值在 25.0-54.7%之间存在重叠。我们的数据表明,相当一部分 PV 患者可能因仅使用红细胞值而被漏诊。在我们机构,对 410 例潜在 PV 患者中的 199 例进行了骨髓活检,对 225 例进行了血清促红细胞生成素值测量。在没有同位素研究的情况下,骨髓活检和血清促红细胞生成素值应提高诊断准确性并成为强制性的,但临床数据表明这些检查并未常规进行。因此,临床血液学家在使用红细胞值来区分原发性血小板增多症 V617F 和 PV 时,必须意识到准确性存在缺陷。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20c8/6821600/c572c0f5aa4d/1042200.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20c8/6821600/d7a248ed6f70/1042200.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20c8/6821600/c572c0f5aa4d/1042200.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20c8/6821600/d7a248ed6f70/1042200.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20c8/6821600/c572c0f5aa4d/1042200.fig2.jpg

相似文献

1
Distinguishing essential thrombocythemia V617F from polycythemia vera: limitations of erythrocyte values.区分 V617F 型原发性血小板增多症与真性红细胞增多症:红细胞值的局限性。
Haematologica. 2019 Nov;104(11):2200-2205. doi: 10.3324/haematol.2018.213108. Epub 2019 Apr 4.
2
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病(MPD)、原发性血小板增多症(ET)、真性红细胞增多症(PV)和慢性特发性骨髓纤维化(CIMF)的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
3
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.区分 JAK2 突变患者中的原发性血小板增多症和隐匿性真性红细胞增多症。
Am J Hematol. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. Epub 2014 Mar 3.
4
Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.克隆分析揭示 JAK2V617F 纯合子与真性红细胞增多症和原发性血小板增多症中血液学特征、年龄和性别相关。
Haematologica. 2013 May;98(5):718-21. doi: 10.3324/haematol.2012.079129.
5
Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).JAK2V617F突变负荷对中国JAK2V617F阳性真性红细胞增多症(PV)和原发性血小板增多症(ET)患者疾病表型的影响
Int J Med Sci. 2016 Jan 25;13(1):85-91. doi: 10.7150/ijms.10539. eCollection 2016.
6
The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.骨髓活检及JAK2V617F突变在真性红细胞增多症“早期”红细胞增多前期与原发性血小板增多症鉴别诊断中的意义
Am J Clin Pathol. 2008 Sep;130(3):336-42. doi: 10.1309/6BQ5K8LHVYAKUAF4.
7
Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.真性红细胞增多症患者中JAK2V617F的鉴定与真性红细胞增多症的传统诊断标准高度相关。
Am J Hematol. 2007 Jan;82(1):80-2. doi: 10.1002/ajh.20721.
8
[Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].[真性红细胞增多症和原发性血小板增多症患者JAK2V617F突变负荷与临床特征的相关性]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):742-5.
9
Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症患者在羟基脲治疗期间JAK2V617F水平迅速下降。
Haematologica. 2008 Aug;93(8):1260-1. doi: 10.3324/haematol.12801. Epub 2008 Jun 2.
10
Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.干扰素α-2b对携带JAK2V617F阳性突变的晚期原发性血小板增多症和真性红细胞增多症获得高持续缓解治疗。
Leuk Res. 2014 Oct;38(10):1177-83. doi: 10.1016/j.leukres.2014.06.019. Epub 2014 Jul 15.

引用本文的文献

1
Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK.英国真性红细胞增多症和原发性血小板增多症患者外周血细胞计数的纵向趋势
EJHaem. 2022 Jun 29;3(3):785-793. doi: 10.1002/jha2.519. eCollection 2022 Aug.
2
Altered Ca Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis.真性红细胞增多症患者终末红细胞生成过程中细胞器分拣紊乱导致红细胞内钙稳态改变。
Cells. 2021 Dec 24;11(1):49. doi: 10.3390/cells11010049.
3
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.

本文引用的文献

1
Polycythemia Vera.真性红细胞增多症。
Curr Treat Options Oncol. 2018 Mar 7;19(2):12. doi: 10.1007/s11864-018-0529-x.
2
Myeloproliferative Neoplasms.骨髓增殖性肿瘤
N Engl J Med. 2017 Aug 31;377(9):895-6. doi: 10.1056/NEJMc1708485.
3
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.欧洲白血病网络研究在蒙面真性红细胞增多症和特发性血小板增多症中的骨髓特征的可重复性及两者的鉴别诊断。
原发性血小板增多症纤维化进展的临床和分子预测因素:一项涉及 1607 例患者的多中心研究。
Am J Hematol. 2021 Nov 1;96(11):1472-1480. doi: 10.1002/ajh.26332. Epub 2021 Sep 6.
4
Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.骨髓增殖性肿瘤概述:历史、发病机制、诊断标准及并发症。
Hematol Oncol Clin North Am. 2021 Apr;35(2):159-176. doi: 10.1016/j.hoc.2020.12.001. Epub 2021 Jan 26.
5
Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?真性红细胞增多症与原发性血小板增多症鉴别诊断中红细胞计数和红细胞量恢复正常的时间?
Haematologica. 2019 Nov;104(11):2119-2125. doi: 10.3324/haematol.2019.229039.
Am J Hematol. 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837. Epub 2017 Jul 29.
4
Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera.根据2016年世界卫生组织真性红细胞增多症诊断标准评估血清促红细胞生成素值。
Leuk Lymphoma. 2017 Nov;58(11):2768-2769. doi: 10.1080/10428194.2017.1300892. Epub 2017 Mar 20.
5
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.评估骨髓形态对于评估重组干扰素α治疗的真性红细胞增多症患者的疾病状态至关重要。
Haematologica. 2017 Mar;102(3):e97-e99. doi: 10.3324/haematol.2016.153973. Epub 2016 Nov 3.
6
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
7
The hematocrit value in polycythemia vera: caveat utilitor.真性红细胞增多症中的血细胞比容值:使用需谨慎。
Leuk Lymphoma. 2015 May;56(5):1540-1. doi: 10.3109/10428194.2014.966243. Epub 2014 Oct 30.
8
The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.血清促红细胞生成素水平及JAK2 V617F等位基因负荷在真性红细胞增多症诊断中的作用。
Br J Haematol. 2014 Nov;167(3):411-7. doi: 10.1111/bjh.13047. Epub 2014 Jul 18.
9
WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.世界卫生组织(WHO)髓系增殖性肿瘤的组织学标准:可重复性、诊断准确性及其与基因突变和临床结果的相关性。
Br J Haematol. 2014 Sep;166(6):911-9. doi: 10.1111/bjh.12990. Epub 2014 Jun 24.
10
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.根据世界卫生组织修订分类标准诊断为血红蛋白水平升高的原发性血小板增多症。
Leukemia. 2014 Oct;28(10):2092-4. doi: 10.1038/leu.2014.175. Epub 2014 Jun 3.